Computer-aided detection (CAD) software developer iCAD is highlighting a study indicating its ProFound artificial intelligence (AI) product for 2D mammography may reduce the risk of interval breast cancer. The retrospective analysis was published in the Journal of Medical Screening.
Interval breast cancers are cancers diagnosed after a negative mammography screening but before the next recommended screening exam. They can be linked to a poor prognosis, such as cancer that has already spread or more aggressive types of cancers.
The aim of the study was to determine if adding AI to reading mammography as a supportive tool may help in decreasing the interval cancer rate in population-based organized mammography screening programs in Germany.
Results suggest that the ProFound AI for 2D Mammography software may help detect 48% of interval cancers and 93% of subgroups that include false negatives and minimal-sign lesions.
Using the technology at the screening level could limit the number of false negatives and help detect a large proportion of the minimal sign cancers, which could ensure earlier treatment and better chances of recovery for these women, according to the company.
